Boehringer Ingelheim Greece
This sponsor has funded 5 studies across 1 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 12887 | Finalised | Not included in RMP | A Multicentre, Cohort Study to Assess the Impact on SYMptom Burden and Patient Health-related Quality of Life of Afatinib Treatment in Advanced... | No | No |
| 17015 | Ongoing | Not included in RMP | Investigating idiopathic pulmonary fibrosis in Greece (INDULGE IPF) | No | No |
| 25664 | Ongoing | Not included in RMP | Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib (QUALIFY IPF) | No | No |
| 28719 | Ongoing | Not included in RMP | Changes in functional status in patients with COPD during therapy with Spiolto® Respimat® (Ellacto study) | Yes | No |
| 38426 | Ongoing | Not included in RMP | Quality of life and preference of COPD patients after Switching from Tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with Tiotropium... | No | No |
PAS by Risk Management Plan (RMP) requirement
Boehringer Ingelheim Greece
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Boehringer Ingelheim Greece
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Boehringer Ingelheim Greece
1 Study countries specified are the following:
- Greece